Review reveals real-world results of new, incisionless liver cancer treatment (IMAGE)
Caption
UVA Health’s Allan Tsung, MD, and colleagues examined outcomes from 972 patients who underwent histotripsy between 2023 and 2026, looking at factors such as patient survival, liver function before and after and the chances of kidney injury.
Credit
UVA Health
Usage Restrictions
May be used to accompany news coverage of the histotripsy findings. All other uses require express written consent from UVA Health.
License
Original content